Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (Nasdaq: SMTI) is a medical technology company that regularly issues news and updates about its surgical, chronic wound and skin-focused business. Company announcements describe a portfolio of surgical tissue repair and advanced wound care products, including CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix and several biologic bone and soft tissue matrices.
News releases often cover developments in Sanara’s commercial strategy and product adoption. For example, the company has reported on growth in soft tissue repair product sales driven by increased demand for CellerateRX Surgical and BIASURGE, expansion into additional medical facilities and the development of an independent distribution network in U.S. markets. Updates also include information on contracts and partnerships, such as an Innovative Technology contract from Vizient® Inc. for BIASURGE, which provides Vizient’s healthcare facility customers with access to the product at contracted pricing and pre-negotiated terms.
Sanara’s news flow includes financial result announcements, where it discusses segment performance, revenue trends and the impact of its strategic realignment. The company has reported the discontinuation of its Tissue Health Plus (THP) operations and the classification of THP as discontinued operations, emphasizing a renewed focus on its core surgical business. Management commentary in these releases outlines priorities related to operating efficiency and capital allocation toward surgical products.
In addition, Sanara issues updates on its product pipeline and alliances, such as its exclusive U.S. license and distribution agreement for OsStic™ Synthetic Injectable Structural Bio-Adhesive and related internal fixation technology. Investors and observers can use the SMTI news page to follow product-related announcements, financial disclosures, strategic decisions and conference participation updates that the company provides through press releases.
Sanara MedTech Inc. (OTCQB: SMTI) reported its Q2 2020 results, revealing a 2% revenue decline to $2.97 million due to COVID-19's impact, despite a record sales month in June. Year-to-date revenue increased by 18% to $6.49 million. The company has reduced costs significantly and expanded its sales force from 9 to 21 regional managers. BIAKŌS™ products showed promising results against SARS-CoV-2 and human coronavirus. Despite a net loss of $1.13 million for Q2, Sanara aims to offset SG&A expenses as new hires begin generating revenue.